CY1113792T1 - Φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης περιλαμβανουσες εστερα φουμαρικου οξεος - Google Patents
Φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης περιλαμβανουσες εστερα φουμαρικου οξεοςInfo
- Publication number
- CY1113792T1 CY1113792T1 CY20121100740T CY121100740T CY1113792T1 CY 1113792 T1 CY1113792 T1 CY 1113792T1 CY 20121100740 T CY20121100740 T CY 20121100740T CY 121100740 T CY121100740 T CY 121100740T CY 1113792 T1 CY1113792 T1 CY 1113792T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical compositions
- controlled frequency
- frequency included
- fumar acid
- acid este
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με φαρμακευτικές συνθέσεις ελεγχόμενης απελευθέρωσης που περιλαμβάνουν εστέρα(ες) φουμαρικού οξέος ως δραστική(ές) ουσία(ες). Οι συνθέσεις είναι κατάλληλες για χρήση στην αγωγή π.χ. ψωρίασης ή άλλων υπερπολλαπλασιαστικών, φλεγμονωδών ή αυτοάνοσων διαταραχών και είναι σχεδιασμένες για απελευθέρωση του εστέρα φουμαρικού οξέος με ελεγχόμενο τρόπο ώστε να αποφεύγονται τοπικές υψηλές συγκεντρώσεις της δραστικής ουσίας εντός της γαστρεντερικής οδού μετά από χορήγηση από το στόμα, καθιστώντας έτσι δυνατό τον περιορισμό των γαστρεντερικών παρενεργειών.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200401546 | 2004-10-08 | ||
DKPA200401736 | 2004-11-10 | ||
DKPA200500211 | 2005-02-11 | ||
DKPA200500419 | 2005-03-23 | ||
US69151305A | 2005-06-16 | 2005-06-16 | |
EP10182198A EP2316430B8 (en) | 2004-10-08 | 2005-10-07 | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113792T1 true CY1113792T1 (el) | 2016-07-27 |
Family
ID=50726313
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100740T CY1113792T1 (el) | 2004-10-08 | 2012-08-16 | Φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης περιλαμβανουσες εστερα φουμαρικου οξεος |
CY20151100679T CY1116599T1 (el) | 2004-10-08 | 2015-08-04 | Φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης που περιλαμβανουν εστερα φουμαρικου οξεος |
CY2015045C CY2015045I1 (el) | 2004-10-08 | 2015-11-19 | Φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης που περιλαμβανουν εστερα φουμαρικου οξεος |
CY20161100847T CY1117937T1 (el) | 2004-10-08 | 2016-08-30 | Φαρμακευτικες συνθεσεις ελεγχομενης αποδεσμευσης που περιλαμβανουν εστερα φουμαρικου οξεος |
CY20171100493T CY1118887T1 (el) | 2004-10-08 | 2017-05-08 | Φαρμακευτικες συνθεσεις ελεγχομενης αποδεσμευσης οι οποιες περιλαμβανουν εναν εστερα φουμαρικου οξεος |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100679T CY1116599T1 (el) | 2004-10-08 | 2015-08-04 | Φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης που περιλαμβανουν εστερα φουμαρικου οξεος |
CY2015045C CY2015045I1 (el) | 2004-10-08 | 2015-11-19 | Φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης που περιλαμβανουν εστερα φουμαρικου οξεος |
CY20161100847T CY1117937T1 (el) | 2004-10-08 | 2016-08-30 | Φαρμακευτικες συνθεσεις ελεγχομενης αποδεσμευσης που περιλαμβανουν εστερα φουμαρικου οξεος |
CY20171100493T CY1118887T1 (el) | 2004-10-08 | 2017-05-08 | Φαρμακευτικες συνθεσεις ελεγχομενης αποδεσμευσης οι οποιες περιλαμβανουν εναν εστερα φουμαρικου οξεος |
Country Status (19)
Country | Link |
---|---|
US (29) | US20140099364A2 (el) |
EP (9) | EP3459532A1 (el) |
JP (5) | JP2008515822A (el) |
CY (5) | CY1113792T1 (el) |
DE (4) | DE14172390T1 (el) |
DK (4) | DK2316430T3 (el) |
ES (5) | ES2387192T3 (el) |
FR (1) | FR15C0074I2 (el) |
HK (1) | HK1108836A1 (el) |
HR (1) | HRP20170677T1 (el) |
HU (3) | HUE031950T2 (el) |
LT (2) | LT1799196T (el) |
LU (1) | LU92871I2 (el) |
ME (2) | ME02746B (el) |
PL (4) | PL2801355T3 (el) |
PT (4) | PT1799196T (el) |
RS (2) | RS54187B1 (el) |
SI (4) | SI2801354T1 (el) |
WO (1) | WO2006037342A2 (el) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
ITMI20022394A1 (it) | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
ITMI20110713A1 (it) | 2011-04-29 | 2012-10-30 | Bracco Imaging Spa | Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina |
ATE380027T1 (de) | 2003-09-09 | 2007-12-15 | Fumapharm Ag | Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma |
DE14172390T1 (de) * | 2004-10-08 | 2014-12-31 | Forward Pharma A/S | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
EP1951206A1 (en) * | 2005-10-07 | 2008-08-06 | Aditech Pharma AB | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
CN101365432B (zh) * | 2005-12-16 | 2011-06-22 | 默沙东公司 | 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物 |
US20070142905A1 (en) * | 2005-12-16 | 2007-06-21 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
ES2511792T3 (es) | 2006-07-25 | 2014-10-23 | Vecta Ltd. | Composiciones y métodos para la inhibición de la secreción de ácido gástrico usando derivados de pequeños ácidos dicarboxílicos en combinación con IBP |
EP3135282A1 (en) | 2007-02-08 | 2017-03-01 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
EP2680006A1 (en) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Treatment for Amyotrophic Lateral Sclerosis |
US8148414B2 (en) | 2008-08-19 | 2012-04-03 | Xenoport, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
US8906420B2 (en) * | 2009-01-09 | 2014-12-09 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
US20120034274A1 (en) * | 2009-01-09 | 2012-02-09 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
HK1252751A1 (zh) * | 2009-01-09 | 2019-05-31 | Fwp Ip Aps | 包含溶蝕骨架中的一種或多種富馬酸酯的藥物製劑 |
CA2760133A1 (en) | 2009-04-29 | 2010-11-04 | Biogen Idec Ma Inc. | Treatment of neurodegeneration and neuroinflammation |
WO2011100589A1 (en) | 2010-02-12 | 2011-08-18 | Biogen Idec Ma Inc. | Neuroprotection in demyelinating diseases |
KR101855805B1 (ko) * | 2010-03-09 | 2018-06-25 | 엘커메스 파마 아일랜드 리미티드 | 알콜 저항성 장용 제약학적 조성물 |
MX348467B (es) * | 2011-04-08 | 2017-06-13 | Bracco Imaging Spa | Proceso para la preparación de un derivado sulfatado de 3,5-diiodo-o-[3-iodofenil]-l-tirosina. |
NZ618178A (en) | 2011-06-08 | 2016-03-31 | Biogen Ma Inc | Process for preparing high purity and crystalline dimethyl fumarate |
RU2014125430A (ru) | 2011-11-24 | 2015-12-27 | Синтон Бв | Контролируемое высвобождение частиц, содержащих диметилфумарат |
EP2782561A1 (en) * | 2011-11-24 | 2014-10-01 | Synthon BV | Controlled release particles comprising dimethyl fumarate |
US20130158077A1 (en) * | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
TWI486339B (zh) | 2012-02-07 | 2015-06-01 | Xenoport Inc | □啉烷基反丁烯二酸化合物、醫藥組成物以及使用之方法 |
NZ627980A (en) * | 2012-02-07 | 2016-12-23 | Biogen Ma Inc | Pharmaceutical compositions containing dimethyl fumarate |
WO2014031897A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Oral dosage forms having a high loading of (n,n- diethylcarbamoyl)methyl methyl|(2e)but-2-ene-1,4-dioate |
EP2887934A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
TW201436790A (zh) | 2012-12-21 | 2014-10-01 | Biogen Idec Inc | 經氘取代之反丁烯二酸酯衍生物類 |
US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
NZ631337A (en) | 2013-03-14 | 2017-01-27 | Alkermes Pharma Ireland Ltd | Prodrugs of fumarates and their use in treating various diseases |
US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
CA2919381A1 (en) * | 2013-08-01 | 2015-02-05 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
EA201690102A1 (ru) * | 2013-08-26 | 2016-06-30 | Форвард Фарма А/С | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе |
EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
EP3079666B1 (en) * | 2013-12-12 | 2021-02-03 | Almirall S.A. | Pharmaceutical compositions comprising dimethyl fumarate |
EP3079663A1 (en) * | 2013-12-13 | 2016-10-19 | Biogen MA Inc. | Controlled release dosage form for once daily administration of dimethyl fumarate |
CA2940845C (en) | 2014-02-24 | 2019-09-24 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
AU2015222880B2 (en) * | 2014-02-28 | 2016-11-24 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
US10391160B2 (en) | 2014-03-14 | 2019-08-27 | Biogen Ma Inc. | Dimethyl fumarate and vaccination regimens |
US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
US20150298008A1 (en) * | 2014-04-16 | 2015-10-22 | Zynga Inc. | Systems and methods of incentivizing game play |
AU2015328676B2 (en) * | 2014-10-08 | 2017-07-20 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
MA40982A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
KR102283582B1 (ko) | 2014-12-23 | 2021-07-30 | 한미약품 주식회사 | 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제 |
WO2016113754A2 (en) * | 2015-01-14 | 2016-07-21 | Leiutis Pharmaceuticals Pvt, Ltd. | Novel oral dosage forms of dimethyl fumarate |
SI3253377T1 (sl) * | 2015-02-08 | 2021-08-31 | Alkermes Pharma Ireland Limited | Monometilfumaratni sestavki predzdravil |
AU2016231883B2 (en) * | 2015-03-17 | 2019-03-07 | Hetero Labs Limited | Pharmaceutical compositions of dimethyl fumarate |
MA41785A (fr) * | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
AU2016273068A1 (en) * | 2015-06-01 | 2017-12-21 | Sun Pharmaceutical Industries Ltd. | Pharmaceutical compositions of dimethyl fumarate |
KR20180018711A (ko) * | 2015-06-17 | 2018-02-21 | 바이오젠 엠에이 인코포레이티드 | 디메틸 푸마레이트 입자 및 이들의 약제학적 조성물 |
US10213411B2 (en) | 2015-08-27 | 2019-02-26 | Vijaykumar Rajasekhar | Use of prodrugs of fumarates in treating heart failure diseases |
WO2017060420A1 (en) | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected fumaric acid-based metabolites for the treatment of autoimmune diseases |
EP3407873A1 (en) * | 2016-01-28 | 2018-12-05 | Zaklady Farmaceutyczne Polpharma SA | Process for preparation of a granulate comprising dimethyl fumarate |
US10463642B2 (en) | 2016-02-01 | 2019-11-05 | Vijaykumar Rajasekhar | Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate |
EA201891803A1 (ru) * | 2016-02-11 | 2019-01-31 | Байоджен Ма Инк. | Фармацевтические составы в форме гранул, содержащие диметилфумарат |
WO2018234584A1 (en) | 2017-06-23 | 2018-12-27 | Almirall, S.A. | PHARMACEUTICAL COMPOSITIONS CONTAINING DIMETHYL FUMARATE |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
TR201818293A2 (tr) * | 2018-11-30 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül |
RU2742745C1 (ru) * | 2019-09-24 | 2021-02-10 | Акционерное общество "Исследовательский Институт Химического Разнообразия" | Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом |
US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
JP2023525079A (ja) | 2020-05-06 | 2023-06-14 | アンシス・エスア | フマレート関連疾患の併用療法 |
CN117597106A (zh) | 2021-05-28 | 2024-02-23 | 美国安进公司 | 阿普斯特配制品 |
WO2023084320A1 (en) * | 2021-11-11 | 2023-05-19 | V-Ensure Pharma Technologies Private Limited | Reconstitutable, single use antidiabetic compositions |
US20240010618A1 (en) * | 2021-12-23 | 2024-01-11 | Glenmark Lofe Science Limited | Process for the preparation of brivaracetam |
CN116524199B (zh) * | 2023-04-23 | 2024-03-08 | 江苏大学 | 一种基于PReNet渐进式网络的图像去雨方法及装置 |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2764609A (en) * | 1953-07-24 | 1956-09-25 | Monsanto Chemicals | Isomerization of dialkyl maleates to dialkyl fumarates |
US3078302A (en) * | 1958-09-25 | 1963-02-19 | Monsanto Chemicals | Production of dialkyl fumarates |
GB1153927A (en) | 1966-08-25 | 1969-06-04 | Wilhelm Hoerrmann | Medicinal Composition Suitable For Treating Diseases Of The Retina |
US4952594A (en) * | 1973-06-18 | 1990-08-28 | Mercer James B | Reagents and method for therapeutic treatment of multiple sclerosis |
DE2530372A1 (de) | 1975-07-08 | 1977-01-13 | Walter Dr Schweckendiek | Pharmazeutische zubereitungen zur behandlung von psoriasis |
DE2703964A1 (de) | 1975-07-08 | 1978-08-03 | Walter Dr Schweckendiek | Pharmazeutische zubereitungen zur behandlung von psoriasis |
US4145438A (en) * | 1975-09-10 | 1979-03-20 | Fisons Limited | Method for treatment of eczema or psoriasis |
DE2621214C3 (de) | 1976-05-13 | 1981-11-12 | Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen | Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen |
DE2732131A1 (de) | 1977-07-15 | 1979-01-25 | Bayer Ag | Verfahren zur herstellung von seitenstaendige hydroxylgruppen aufweisenden isocyanat-polyadditionsprodukten |
DE2749188C2 (de) | 1977-11-03 | 1981-11-12 | Bayer Ag, 5090 Leverkusen | Vorrichtung zum automatischen Einführen eines schnellaufenden Fadens in einen Fadenführungskanal einer Fadenbehandlungsvorrichtung |
DE2840498C2 (de) | 1978-09-18 | 1980-04-10 | Walter Dr. 6700 Ludwigshafen Schweckendiek | Pharmazeutische Zubereitungen zur Behandlung von Psoriasis |
US4302440B1 (en) * | 1980-07-31 | 1986-08-05 | Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof | |
US5149695A (en) * | 1985-01-15 | 1992-09-22 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
CH664150A5 (de) * | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
US4693896A (en) | 1985-10-07 | 1987-09-15 | Fmc Corporation | Ethylcellulose-coated, gastric-disintegrable aspirin tablet |
US4855305A (en) | 1987-03-23 | 1989-08-08 | Applied Medical Research | Compositions and methods of effecting contraception utilizing melatonin |
DE3711155A1 (de) * | 1987-04-02 | 1988-10-13 | Bayer Ag | Verfahren zur herstellung von maleinsaeuredimethylester |
IL83775A (en) | 1987-09-04 | 1991-12-15 | Dexter Chemical Corp | Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis |
US5214196A (en) * | 1987-09-04 | 1993-05-25 | Dexter Chemical Corporation | Diethyl ester of di-glycyl fumaramide |
US5242905A (en) * | 1987-09-04 | 1993-09-07 | Dexter Chemical Corporation | Pharmaceutical compositions for the treatment of psoriasis |
US5424332A (en) * | 1987-10-19 | 1995-06-13 | Speiser; Peter P. | Pharmaceutical composition and process for the production thereof |
US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
US4911917A (en) * | 1988-06-28 | 1990-03-27 | Hauser-Kuhrts, Inc. | Cholesterol-lowering combination comopsitions of magnesium salt and niacin |
US4965252A (en) | 1988-06-28 | 1990-10-23 | Hauser-Kuhrts, Inc. | Cholesterol-lowering combination compositions of guar gum and niacin |
US5023245A (en) * | 1987-11-10 | 1991-06-11 | Hauser-Kuhrts, Inc. | Improved niacin formulation |
DE3834794A1 (de) | 1988-10-12 | 1990-04-19 | F Schielein | Oral zu verabreichendes mittel zur behandlung von psoriasis |
US5484610A (en) | 1991-01-02 | 1996-01-16 | Macromed, Inc. | pH and temperature sensitive terpolymers for oral drug delivery |
GEP19971086B (en) | 1991-02-22 | 1997-12-02 | Tillotts Pharma Ag | Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine |
US5246947A (en) * | 1991-09-23 | 1993-09-21 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression |
FR2694693B1 (fr) | 1992-07-28 | 1994-10-28 | Abrax Bio Labs Sa | Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH. |
ES2149250T3 (es) * | 1993-04-23 | 2000-11-01 | Novartis Ag | Dispositivo para la administracion de medicamentos con liberacion controlada. |
US5434185A (en) | 1993-05-17 | 1995-07-18 | The University Of Kentucky Research Foundation | Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts |
US6068859A (en) * | 1994-05-06 | 2000-05-30 | Pfizer Inc. | Controlled-release dosage forms of Azithromycin |
US5589504A (en) * | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
US5716625A (en) | 1994-12-21 | 1998-02-10 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US5804203A (en) | 1994-12-21 | 1998-09-08 | Cosmederm Technologies | Topical product formulations containing strontium for reducing skin irritation |
US6139850A (en) * | 1994-12-21 | 2000-10-31 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
EP0737471A3 (fr) * | 1995-04-10 | 2000-12-06 | L'oreal | Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue |
AU5787996A (en) | 1995-04-19 | 1996-11-07 | Lipoprotein Technologies, Inc. | Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs |
FR2749759B1 (fr) * | 1996-06-17 | 1999-11-26 | Adir | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose |
GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
JP2001527517A (ja) | 1996-07-26 | 2001-12-25 | スーザン・ピー・ペリーネ | 血液、ウイルス性および細胞性疾患の治療組成物 |
WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
NZ333474A (en) * | 1998-01-02 | 1999-06-29 | Mcneil Ppc Inc | A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat |
SI1051159T1 (en) | 1998-01-22 | 2002-10-31 | Zentaris Ag | Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
DE19814358C2 (de) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
EP1067910B1 (en) * | 1998-04-03 | 2004-05-26 | Egalet A/S | Controlled release composition |
US20050220909A1 (en) * | 2004-03-30 | 2005-10-06 | Theoharides Theoharis C | Composition for protection against superficial vasodilator flush syndrome |
DE19839566C2 (de) | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
KR100297705B1 (ko) * | 1999-03-29 | 2001-10-29 | 김덕중 | 낮은 온저항과 높은 항복전압을 갖는 전력용 반도체소자 |
US6537584B1 (en) | 1999-11-12 | 2003-03-25 | Macromed, Inc. | Polymer blends that swell in an acidic environment and deswell in a basic environment |
DE10000577A1 (de) * | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
WO2001060780A1 (fr) * | 2000-02-15 | 2001-08-23 | Showa Denko K.K. | Procede de production d'ester fumarique |
CN1951899B (zh) * | 2000-02-16 | 2012-02-01 | 布里格姆及妇女医院股份有限公司 | 阿司匹林触发的脂质介体 |
IT1317042B1 (it) | 2000-06-14 | 2003-05-26 | Biosalts Srl | Fumarati doppi di una carnitina e creatina, e integratori alimentari,dietetici e farmaci che li contengono. |
EP1172101A1 (en) * | 2000-06-20 | 2002-01-16 | Helsinn Healthcare S.A. | The use of nimesulide for the treatment of psoriasis and psoriatic arthritis |
AU2001271824A1 (en) * | 2000-07-05 | 2002-01-14 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
WO2002032374A2 (en) * | 2000-10-18 | 2002-04-25 | Immunex Corporation | Methods for treating il-18 mediated disorders |
DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
US7157423B2 (en) | 2001-01-12 | 2007-01-02 | Fumapharm Ag | Fumaric acid amides |
SE0100200D0 (sv) | 2001-01-24 | 2001-01-24 | Astrazeneca Ab | New film coating |
CN100579514C (zh) | 2001-07-06 | 2010-01-13 | 生命周期药物公司 | 通过受控制的凝聚而制备颗粒物的方法以及提高生物利用度的方法 |
NO20014746D0 (no) | 2001-09-28 | 2001-09-28 | Clas M Kjoelberg | Smertelindrende middel |
US7206276B2 (en) * | 2001-10-12 | 2007-04-17 | Konica Corporation | Objective lens, optical element, optical pick-up apparatus and optical information recording and/or reproducing apparatus equipped therewith |
US20030152622A1 (en) | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
WO2003041705A1 (en) | 2001-11-13 | 2003-05-22 | Pharmacia Corporation | Oral dosage form of a sulfonamide prodrug such as parecoxib |
US6613800B1 (en) * | 2001-12-03 | 2003-09-02 | Steven A. Smith | Method and compositions for treating psoriasis, eczema, seborrhea and arthritis |
KR100540035B1 (ko) | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | 다단계 경구 약물 방출 제어 시스템 |
EP1485078B1 (en) | 2002-03-15 | 2012-09-26 | Cypress Bioscience, Inc. | Milnacipran for the treatment of irritable bowel syndrome |
DE10214031A1 (de) | 2002-03-27 | 2004-02-19 | Pharmatech Gmbh | Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation |
US20030185915A1 (en) * | 2002-03-28 | 2003-10-02 | Jaime Carlo | Synergetic composition for the treatment of psoriasis and other skin disorders and method therefor |
DE10217314A1 (de) * | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
US20030219456A1 (en) * | 2002-05-21 | 2003-11-27 | Taing Ok | Method of utilization of zygosaccharomyces rouxii |
US20040038904A1 (en) * | 2002-05-21 | 2004-02-26 | Angela Ogden | Method of treating multiple sclerosis |
US6830759B2 (en) | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
US7235560B2 (en) | 2002-08-19 | 2007-06-26 | Glaxo Group Limited | Pyrimidine derivative as selective COX-2 inhibitors |
JP4750691B2 (ja) | 2003-03-27 | 2011-08-17 | サントソルヴ エーエス | 抗炎症治療 |
DK2266584T3 (da) | 2003-05-07 | 2013-01-02 | Osteologix As | Sammensætning med strontium og D-vitamin til profylakse og/eller behandling af brusk- og knogletilstande |
DE602004002832T2 (de) | 2003-05-07 | 2007-06-06 | Osteologix A/S | Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen |
AU2004237437B2 (en) | 2003-05-07 | 2011-01-20 | Osteologix A/S | Controlled release composition containing a strontium salt |
AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
EP1575565B1 (en) | 2003-08-08 | 2010-01-06 | Biovail Laboratories International Srl | Modified-release tablet of bupropion hydrochloride |
ATE380027T1 (de) | 2003-09-09 | 2007-12-15 | Fumapharm Ag | Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma |
CN1938006B (zh) | 2004-03-31 | 2010-11-10 | Bpsi控股公司 | 用于口服摄取基质的肠溶包衣 |
TW200603792A (en) | 2004-04-23 | 2006-02-01 | Pharmacia & Upjohn Co Llc | Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors |
CN1245873C (zh) | 2004-08-21 | 2006-03-22 | 王立峰 | 富马酸二甲酯微胶囊及其制备方法 |
DE14172390T1 (de) * | 2004-10-08 | 2014-12-31 | Forward Pharma A/S | Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester |
CN101056624A (zh) | 2004-10-08 | 2007-10-17 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
US20080004344A1 (en) * | 2004-11-10 | 2008-01-03 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
WO2006050730A1 (en) | 2004-11-10 | 2006-05-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
DE102005022845A1 (de) * | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiobernsteinsäurederivate und deren Verwendung |
US20070071819A1 (en) * | 2005-05-30 | 2007-03-29 | Kesarwani Amit K | Multiple unit modified release compositions of carbamazepine and process for their preparation |
CA2614110A1 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
EP1915387B1 (en) * | 2005-07-07 | 2010-01-20 | Aditech Pharma AG | Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use |
EP1915334A2 (en) | 2005-07-07 | 2008-04-30 | Aditech Pharma AB | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
WO2007042035A2 (en) | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
EP1951206A1 (en) | 2005-10-07 | 2008-08-06 | Aditech Pharma AB | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
WO2007094632A1 (en) * | 2006-02-15 | 2007-08-23 | Md Bioalpha Co., Ltd. | Method for controlling nad(p)/nad(p)h ratio by oxidoreductase |
WO2007148744A1 (ja) | 2006-06-21 | 2007-12-27 | Santen Pharmaceutical Co., Ltd. | フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤 |
MX2009002299A (es) | 2006-09-01 | 2009-03-20 | Cv Therapeutics Inc | Metodos y composiciones para incrementar la tolerancia del paciente durante metodos de formacion de imagenes del miocardio. |
EP2680006A1 (en) | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Treatment for Amyotrophic Lateral Sclerosis |
EP3135282A1 (en) | 2007-02-08 | 2017-03-01 | Biogen MA Inc. | Neuroprotection in demyelinating diseases |
WO2008129698A1 (ja) | 2007-04-12 | 2008-10-30 | Panasonic Corporation | 電源システムおよび組電池の充電方法 |
DE202008018063U1 (de) | 2007-04-25 | 2011-10-11 | Teva Pharmaceutical Industries Ltd. | Pharmazeutischer Hilfsstoffkomplex |
US20080274182A1 (en) | 2007-05-03 | 2008-11-06 | Regina Helena Alida Boekema | Tablet coatings made from modified carboxymethylcellulose materials |
JP2010532358A (ja) | 2007-07-01 | 2010-10-07 | ピーター ハバウシ,ジョセフ | 咀嚼可能外層を有する配合剤 |
KR20090028047A (ko) * | 2007-09-13 | 2009-03-18 | 경북대학교 산학협력단 | 디메틸푸마레이트의 신규 용도 |
CN101318901A (zh) | 2008-06-17 | 2008-12-10 | 健雄职业技术学院 | 一种富马酸二甲酯的合成新工艺 |
US8148414B2 (en) * | 2008-08-19 | 2012-04-03 | Xenoport, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
US20120034274A1 (en) * | 2009-01-09 | 2012-02-09 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
US8906420B2 (en) | 2009-01-09 | 2014-12-09 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
CN101475477A (zh) | 2009-01-23 | 2009-07-08 | 上海化学试剂研究所 | 反丁烯二酸二甲酯的制备方法 |
WO2010113096A1 (en) * | 2009-03-30 | 2010-10-07 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
CA2760133A1 (en) * | 2009-04-29 | 2010-11-04 | Biogen Idec Ma Inc. | Treatment of neurodegeneration and neuroinflammation |
CN101701943A (zh) | 2009-11-05 | 2010-05-05 | 宁波中普检测技术服务有限公司 | 气相色谱-质谱联用测定产品中富马酸二甲酯的方法 |
WO2011100589A1 (en) | 2010-02-12 | 2011-08-18 | Biogen Idec Ma Inc. | Neuroprotection in demyelinating diseases |
BR112013030169A2 (pt) | 2011-05-26 | 2016-08-09 | Biogen Idec Inc | métodos de tratamento de esclerose múltipla e preservação e/ou aumento do teor de mielina |
NZ618178A (en) | 2011-06-08 | 2016-03-31 | Biogen Ma Inc | Process for preparing high purity and crystalline dimethyl fumarate |
RU2014125430A (ru) | 2011-11-24 | 2015-12-27 | Синтон Бв | Контролируемое высвобождение частиц, содержащих диметилфумарат |
NZ627980A (en) | 2012-02-07 | 2016-12-23 | Biogen Ma Inc | Pharmaceutical compositions containing dimethyl fumarate |
EP2887934A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
KR102092289B1 (ko) * | 2013-06-03 | 2020-03-23 | 삼성전자주식회사 | 전자 기기 및 이의 문서 작성 방법 |
EP3079663A1 (en) | 2013-12-13 | 2016-10-19 | Biogen MA Inc. | Controlled release dosage form for once daily administration of dimethyl fumarate |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
AU2015222880B2 (en) | 2014-02-28 | 2016-11-24 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
AU2015328676B2 (en) | 2014-10-08 | 2017-07-20 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
WO2017040272A1 (en) | 2015-08-31 | 2017-03-09 | Banner Life Sciences Llc | Fumarate ester dosage forms |
WO2017151184A1 (en) | 2016-02-29 | 2017-09-08 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US10523918B2 (en) | 2017-03-24 | 2019-12-31 | Samsung Electronics Co., Ltd. | System and method for depth map |
-
2005
- 2005-10-07 DE DE14172390.8T patent/DE14172390T1/de active Pending
- 2005-10-07 DK DK10182198.1T patent/DK2316430T3/da active
- 2005-10-07 RS RS20150540A patent/RS54187B1/en unknown
- 2005-10-07 EP EP18204738.1A patent/EP3459532A1/en not_active Withdrawn
- 2005-10-07 PT PT57890261T patent/PT1799196T/pt unknown
- 2005-10-07 RS RS20170452A patent/RS55936B1/sr unknown
- 2005-10-07 EP EP10182198A patent/EP2316430B8/en not_active Revoked
- 2005-10-07 ME MEP-2017-102A patent/ME02746B/me unknown
- 2005-10-07 ES ES10182198T patent/ES2387192T3/es active Active
- 2005-10-07 EP EP05789026.1A patent/EP1799196B1/en not_active Revoked
- 2005-10-07 EP EP20140172398 patent/EP2801355B1/en not_active Revoked
- 2005-10-07 PT PT141723981T patent/PT2801355E/pt unknown
- 2005-10-07 US US11/576,871 patent/US20140099364A2/en not_active Abandoned
- 2005-10-07 ES ES14172390.8T patent/ES2525495T3/es active Active
- 2005-10-07 SI SI200532146A patent/SI2801354T1/sl unknown
- 2005-10-07 SI SI200531993T patent/SI2801355T1/sl unknown
- 2005-10-07 PL PL14172398T patent/PL2801355T3/pl unknown
- 2005-10-07 JP JP2007535023A patent/JP2008515822A/ja active Pending
- 2005-10-07 LT LTEP05789026.1T patent/LT1799196T/lt unknown
- 2005-10-07 EP EP18208053.1A patent/EP3470064A1/en not_active Withdrawn
- 2005-10-07 WO PCT/DK2005/000648 patent/WO2006037342A2/en active Search and Examination
- 2005-10-07 ME MEP-2015-540A patent/ME02253B/me unknown
- 2005-10-07 DE DE14172396.5T patent/DE14172396T1/de active Pending
- 2005-10-07 EP EP14172396.5A patent/EP2792349A3/en not_active Ceased
- 2005-10-07 HU HUE14172390A patent/HUE031950T2/en unknown
- 2005-10-07 DK DK14172398.1T patent/DK2801355T3/en active
- 2005-10-07 DK DK05789026.1T patent/DK1799196T3/en active
- 2005-10-07 EP EP16001391.8A patent/EP3093012A1/en not_active Withdrawn
- 2005-10-07 DE DE14172398.1T patent/DE14172398T1/de active Pending
- 2005-10-07 PT PT10182198T patent/PT2316430E/pt unknown
- 2005-10-07 DK DK14172390.8T patent/DK2801354T3/en active
- 2005-10-07 PL PL05789026.1T patent/PL1799196T3/pl unknown
- 2005-10-07 ES ES14172398.1T patent/ES2525497T3/es active Active
- 2005-10-07 EP EP15166243.4A patent/EP2965751A1/en not_active Withdrawn
- 2005-10-07 PT PT141723908T patent/PT2801354T/pt unknown
- 2005-10-07 PL PL14172390T patent/PL2801354T3/pl unknown
- 2005-10-07 HU HUE05789026A patent/HUE028342T2/en unknown
- 2005-10-07 ES ES14172396.5T patent/ES2523796T1/es active Pending
- 2005-10-07 DE DE202005022112.0U patent/DE202005022112U1/de not_active Expired - Lifetime
- 2005-10-07 SI SI200531565T patent/SI2316430T1/sl unknown
- 2005-10-07 LT LTEP14172390.8T patent/LT2801354T/lt unknown
- 2005-10-07 PL PL10182198T patent/PL2316430T3/pl unknown
- 2005-10-07 EP EP14172390.8A patent/EP2801354B1/en not_active Revoked
- 2005-10-07 SI SI200532086A patent/SI1799196T1/sl unknown
- 2005-10-07 ES ES05789026.1T patent/ES2582942T3/es active Active
-
2007
- 2007-12-24 HK HK07114067.2A patent/HK1108836A1/zh not_active IP Right Cessation
-
2012
- 2012-08-16 CY CY20121100740T patent/CY1113792T1/el unknown
- 2012-12-06 JP JP2012267572A patent/JP2013064007A/ja active Pending
-
2013
- 2013-08-01 US US13/957,250 patent/US20140037740A1/en not_active Abandoned
- 2013-08-01 US US13/957,117 patent/US20140037720A1/en not_active Abandoned
- 2013-08-01 US US13/957,147 patent/US20130315993A1/en not_active Abandoned
- 2013-08-01 US US13/957,220 patent/US20130316003A1/en not_active Abandoned
-
2014
- 2014-03-13 US US14/209,712 patent/US20140199386A1/en not_active Abandoned
- 2014-03-13 US US14/209,756 patent/US20140199393A1/en not_active Abandoned
- 2014-03-13 US US14/209,584 patent/US20140200272A1/en not_active Abandoned
- 2014-03-13 US US14/209,651 patent/US20140200273A1/en not_active Abandoned
- 2014-03-13 US US14/209,480 patent/US20170112793A2/en not_active Abandoned
- 2014-03-13 US US14/209,823 patent/US20150024049A1/en not_active Abandoned
- 2014-03-14 US US14/213,321 patent/US20140199387A1/en not_active Abandoned
- 2014-03-14 US US14/213,399 patent/US20140205659A1/en not_active Abandoned
- 2014-03-14 US US14/212,685 patent/US20140199392A1/en not_active Abandoned
- 2014-03-14 US US14/213,673 patent/US20140199388A1/en not_active Abandoned
- 2014-03-14 US US14/212,503 patent/US20140199390A1/en not_active Abandoned
-
2015
- 2015-07-13 JP JP2015139809A patent/JP2015227350A/ja active Pending
- 2015-08-04 CY CY20151100679T patent/CY1116599T1/el unknown
- 2015-11-09 FR FR15C0074C patent/FR15C0074I2/fr active Active
- 2015-11-13 LU LU92871C patent/LU92871I2/xx unknown
- 2015-11-18 HU HUS1500057C patent/HUS1500057I1/hu unknown
- 2015-11-19 CY CY2015045C patent/CY2015045I1/el unknown
-
2016
- 2016-08-30 CY CY20161100847T patent/CY1117937T1/el unknown
-
2017
- 2017-04-28 US US15/581,966 patent/US20170231941A1/en not_active Abandoned
- 2017-05-04 HR HRP20170677TT patent/HRP20170677T1/hr unknown
- 2017-05-08 CY CY20171100493T patent/CY1118887T1/el unknown
- 2017-10-10 US US15/728,872 patent/US20180028483A1/en not_active Abandoned
- 2017-12-07 US US15/834,870 patent/US20180098957A1/en not_active Abandoned
-
2018
- 2018-02-02 JP JP2018017332A patent/JP2018087220A/ja active Pending
- 2018-05-24 US US15/988,628 patent/US20180263947A1/en not_active Abandoned
- 2018-07-26 US US16/046,509 patent/US20180325855A1/en not_active Abandoned
- 2018-11-29 US US16/204,503 patent/US20190091192A1/en not_active Abandoned
- 2018-11-29 US US16/204,559 patent/US20190091193A1/en not_active Abandoned
- 2018-11-29 US US16/204,403 patent/US20190091191A1/en not_active Abandoned
- 2018-12-20 US US16/227,287 patent/US11229619B2/en active Active
-
2019
- 2019-03-06 US US16/294,038 patent/US20190201368A1/en not_active Abandoned
- 2019-05-20 JP JP2019094350A patent/JP6896792B2/ja active Active
- 2019-07-29 US US16/525,392 patent/US11052062B2/en active Active
-
2021
- 2021-02-25 US US17/185,600 patent/US20210220318A1/en not_active Abandoned
- 2021-12-16 US US17/553,367 patent/US20220105064A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113792T1 (el) | Φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης περιλαμβανουσες εστερα φουμαρικου οξεος | |
CY1115891T1 (el) | Φαρμακευτικες συνθεσεις για την αντιμετωπιση των διαταραχων του εσω ωτος | |
CY1115940T1 (el) | Παραγωγα υποκατεστημενου φαινυλαλκανοϊκου οξεος και η χρηση τους για τη θεραπευτικη αντιμετωπιση αναπνευστικων ασθενειων | |
CY1115858T1 (el) | Υποκατεστημενες πιπεριδινο-διυδρο-θειενο-πυριμιδινες | |
CY1112369T1 (el) | 2-μεθυλο-2-[4-(3-μεθυλο-2-οξο-8-κινολιν-3-υλο-2,3-διϋδρο-ιμιδαζο[4,5-c]κινολινυλο)-φαινυλο]προπιονιτριλιο ως αναστολεας λιπιδικης κινασης | |
CY1122349T1 (el) | Παραγωγα 1-benzyλ-3-υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των mcp-1, cxcr1 και ρ40 | |
CY1116103T1 (el) | Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης | |
CY1113267T1 (el) | Παραγωγα θειοφαινιου ως αγωνιστες των υποδοσεων s1p1/edg1 | |
CY1116315T1 (el) | Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3 | |
CY1108324T1 (el) | Νεοι τεταρτοταγοποιημενοι εστερες κουινουκλιδινης | |
DE60303238D1 (de) | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten | |
CY1105617T1 (el) | Νεα αρωματικα παραγωγα των φθορογλυκοσιδων, φαρμακα περιεχοντα αυτες τις ενωσεις και η χρηση τους | |
CY1117584T1 (el) | Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1 | |
CY1107426T1 (el) | Νεα παραγωγα φθοριογλυκοσιδιων απο πυραζολες, φαρμακευτικα προϊοντα που περιεχουν τις εν λογω ενωσεις και η χρηση αυτων | |
CY1111757T1 (el) | Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α | |
EA200601802A1 (ru) | Производные морфолина | |
CY1105362T1 (el) | Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα | |
CY1105621T1 (el) | Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους | |
CY1110812T1 (el) | Παραγωγα διφαινυλοξυοξικου οξεος για τη θεραπεια αναπνευστικων διαταραχων | |
CY1114200T1 (el) | Ναφθυλοοξικα οξεα | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
UA110463C2 (ru) | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНІЛ)-5Н-ПІРИМІДО[5,4-d][2]БЕНЗАЗЕПІН-2-ІЛ]АМІНО}-2-МЕТОКСИБЕНЗОЙНОЇ КИСЛОТИ ДЛЯ ЛІКУВАННЯ РАКУ Й ІНШИХ ЗАХВОРЮВАНЬ І ПОРУШЕНЬ СТАНУ ЗДОРОВ'Я | |
EA200800421A1 (ru) | Соединения | |
CY1117959T1 (el) | 24-norudca για την αγωγη αυτοανοσης ηπατιτιδας | |
CY1112012T1 (el) | Αμινουχα παραγωγα β-ομοανδροστανων και β-ετεροανδροστανων |